Renal Cell Carcinoma

Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.

Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.

Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.

Nazli Dizman, MD, internal medicine resident at Yale Department of Internal Medicine, discusses the role of the gut microbiome in cancers like renal cell carcinoma.

In an interview with Targeted Oncology, Erika P. Hamilton, MD, discussed the early clinical activity seen with DS-6000a in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmD, discussed the most recent data supporting immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations for frontline treatment of patients with renal cell carcinoma.

During a live virtual event, Thomas Hutson, DO, PharmD, discussed the outcomes of the CLEAR trial of lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma.

Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.

Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis of adjuvant pembrolizumab in renal cell carcinoma.

In the phase 3 CheckMate-914 clinical trial, the combination of nivolumab and ipilimumab did not achieve its primary end point of improvement in disease-free survival compared with the placebo control.

During a live virtual event, Thomas Hutson, MD, PharmD, discussed the 4 frontline combination regimens including immunotherapies and tyrosine kinase inhibitors. This is the first of 2 articles based on this live event.

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the approved frontline regimens for patients with advanced clear cell renal cell carcinoma.

During separate virtual live events, Sandy T. Liu, MD, and Moshe Ornstein, MD, MA, discussed what treatment they would choose for a patient with clear cell renal cell carcinoma and the trial data available in this setting.

During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed the case of a patient who progressed following treatment with axitinib and pembrolizumab for clear cell renal cell carcinoma.

During a live virtual event, Ulka N. Vaishampayan, MBBS, discussed the choice of first-line therapy for clear cell renal cell carcinoma and whether the approach to treatment would change with other disease histologies.

Results from the primary analysis of the phase 3 COSMIC-313 trial showed significant improvement in progression-free survival in patients with renal cell carcinoma receiving the combination of cabozantinib, nivolumab, and ipilimumab.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis and what will come next for pembrolizumab treatment in renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed the case of a patient with clear cell renal cell carcinoma who progressed following frontline treatment with axitinib/pembrolizumab.

During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed updates to key trials in advanced clear cell renal cell carcinoma.

Matthew T. Campbell, MD, discusses the results of a retrospective analysis of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation.

During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.

Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.

At a live virtual event, Robert J. Motzer, MD, discussed the risk factors for classifying patients with advanced renal cell carcinoma and data from several phase 3 trials of combination regimens.

Eric Jonasch, MD, further discussed the 2 posters he presented in regard to belzutifan at 2022 ASCO.

During a Targeted Oncology case-based roundtable event, Chandler Park, MD, discussed the preferred first-line treatment options including tyrosine kinase inhibitor/immunotherapy combinations for metastatic clear cell renal cell carcinoma.

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.

Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.

Results from the phase 3 CLEAR trial showed lenvatinib plus everolimus to have a statistically significant improvement in progression-free survival and objective response rate compared with those given sunitinib.

Decreased risk of disease progression or death on second-line therapy with the combination of lenvatinib and pembrolizumab vs sunitinib in the CLEAR clinical trial.